TY - JOUR
T1 - Pivotal role of cerebral interleukin-17-producing T cells in the delayed phase of ischemic brain injury
AU - Shichita, Takashi
AU - Sugiyama, Yuki
AU - Ooboshi, Hiroaki
AU - Sugimori, Hiroshi
AU - Nakagawa, Ryusuke
AU - Takada, Ichiro
AU - Iwaki, Toru
AU - Okada, Yasunori
AU - Iida, Mitsuo
AU - Cua, Daniel J.
AU - Iwakura, Yoichiro
AU - Yoshimura, Akihiko
N1 - Funding Information:
We thank S. Hamano for TCRgd-specific antibody hybridoma, T. Yoshioka, N. Shiino and M. Asakawa for technical assistance, E. Ishikawa and H. Noguchi for technical support for human ischemic brain section, T. Kobayashi for discussion and technical help and N. Soma for manuscript preparation. This study was supported by special Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO, 07-4), the Naito Foundation and the Astellas Foundation for Research on Metabolic Disorders.
PY - 2009/8
Y1 - 2009/8
N2 - Lymphocyte recruitment and activation have been implicated in the progression of cerebral ischemia-reperfusion (I/R) injury, but the roles of specific lymphocyte subpopulations and cytokines during stroke remain to be clarified. Here we demonstrate that the infiltration of T cells into the brain, as well as the cytokines interleukin-23 (IL-23) and IL-17, have pivotal roles in the evolution of brain infarction and accompanying neurological deficits. Blockade of T cell infiltration into the brain by the immunosuppressant FTY720 reduced I/R-induced brain damage. The expression of IL-23, which was derived mostly from infiltrated macrophages, increased on day 1 after I/R, whereas IL-17 levels were elevated after day 3, and this induction of IL-17 was dependent on IL-23. These data, together with analysis of mice genetically disrupted for IL-17 and IL-23, suggest that IL-23 functions in the immediate stage of I/R brain injury, whereas IL-17 has an important role in the delayed phase of I/R injury during which apoptotic neuronal death occurs in the penumbra. Intracellular cytokine staining revealed that T lymphocytes, but not CD4 + helper T cells, were a major source of IL-17. Moreover, depletion of T lymphocytes ameliorated the I/R injury. We propose that T lymphocytes, including T lymphocytes, could be a therapeutic target for mitigating the inflammatory events that amplify the initial damage in cerebral ischemia.
AB - Lymphocyte recruitment and activation have been implicated in the progression of cerebral ischemia-reperfusion (I/R) injury, but the roles of specific lymphocyte subpopulations and cytokines during stroke remain to be clarified. Here we demonstrate that the infiltration of T cells into the brain, as well as the cytokines interleukin-23 (IL-23) and IL-17, have pivotal roles in the evolution of brain infarction and accompanying neurological deficits. Blockade of T cell infiltration into the brain by the immunosuppressant FTY720 reduced I/R-induced brain damage. The expression of IL-23, which was derived mostly from infiltrated macrophages, increased on day 1 after I/R, whereas IL-17 levels were elevated after day 3, and this induction of IL-17 was dependent on IL-23. These data, together with analysis of mice genetically disrupted for IL-17 and IL-23, suggest that IL-23 functions in the immediate stage of I/R brain injury, whereas IL-17 has an important role in the delayed phase of I/R injury during which apoptotic neuronal death occurs in the penumbra. Intracellular cytokine staining revealed that T lymphocytes, but not CD4 + helper T cells, were a major source of IL-17. Moreover, depletion of T lymphocytes ameliorated the I/R injury. We propose that T lymphocytes, including T lymphocytes, could be a therapeutic target for mitigating the inflammatory events that amplify the initial damage in cerebral ischemia.
UR - https://www.scopus.com/pages/publications/68349160698
UR - https://www.scopus.com/pages/publications/68349160698#tab=citedBy
U2 - 10.1038/nm.1999
DO - 10.1038/nm.1999
M3 - Article
C2 - 19648929
AN - SCOPUS:68349160698
SN - 1078-8956
VL - 15
SP - 946
EP - 950
JO - Nature medicine
JF - Nature medicine
IS - 8
ER -